The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks ATF3 and the DNA damage response in cancer cells

摘要

Background and PurposeThe catalytic topoisomerase II inhibitor dexrazoxane has been associated not only with improved cancer patient survival but also with secondary malignancies and reduced tumour response.